Related Experiment Video
Updated: Oct 9, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Advancing Antithrombin Therapy in Acute Myocardial Infarction Management: Low Molecular Weight Heparins Plus
Charanjit Khurana1, Conor F. Lundergan
1Division of Cardiology, Suite # 4-417, George Washington University Medical Center, 2150 Pennsylvania Ave, NW, Washington, DC 20037, USA. domcfl@gwumc.edu
Unfractionated heparin (UFH) has been traditionally used as an antithrombotic agent following fibrinolytic therapy for acute myocardial infarction. However, UFH has pharmacokinetic, biophysical, and biological limitations. Although early infarct artery patency has been superior with UFH as compared with placebo, aggregate data has demonstrated only a modest reduction in clinical events. Low molecular weight heparins (LMWHs) are attractive as potential adjunctive therapy to thrombolysis because of their greater bioavailabilty and ease of administration compared with UFH. Initial small trials with LMWHs have demonstrated their apparent safety when used in combination with thrombolytic agents, and a trend toward higher infarct-related artery patency rates. The clinical efficacy of LMWHs compared with UFH is currently being addressed in large-scale randomized clinical trials.
Unfractionated heparin (UFH) has been traditionally used as an antithrombotic agent following fibrinolytic therapy for acute myocardial infarction. However, UFH has pharmacokinetic, biophysical, and biological limitations. Although early infarct artery patency has been superior with UFH as compared with placebo, aggregate data has demonstrated only a modest reduction in clinical events. Low molecular weight heparins (LMWHs) are attractive as potential adjunctive therapy to thrombolysis because of their greater bioavailabilty and ease of administration compared with UFH. Initial small trials with LMWHs have demonstrated their apparent safety when used in combination with thrombolytic agents, and a trend toward higher infarct-related artery patency rates. The clinical efficacy of LMWHs compared with UFH is currently being addressed in large-scale randomized clinical trials.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Clot Retraction and Fibrinolysis
